Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,037 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cancer Screening Clear all
Completed Not applicable Interventional Results available

Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts

NCT05787249
View directory record Official record
Conditions
Breast Cancer
Interventions
Patient nudge, Provider nudge
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
1,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

NCT03773133
View directory record Official record
Conditions
Small Cell Lung Cancer and Breast Cancer
Interventions
Satoreotide tetraxetan, Satoreotide trizoxetan
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Early Phase 1 Interventional

Non Invasive Oral Cancer Screening Among HIV Infected Individuals

NCT02823847
View directory record Official record
Conditions
Malignant Neoplasms of Mesothelial and Soft Tissue, Human Immunodeficiency Virus
Interventions
Screening Interview, Carbon Monoxide Test, Self-Help Materials, Visual Oral Screening Examination, Direct Fluorescent Oral Visualization Examination, Oral Biopsy
Behavioral · Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 21, 2026, 7:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation

NCT06059963
View directory record Official record
Conditions
Colorectal Cancer, Advanced Adenocarcinoma
Interventions
Signal-C™
Device
Lead sponsor
Universal Diagnostics
Industry
Eligibility
45 Years to 84 Years
Enrollment
12,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Raonoke, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Prostate Cancer Education in African American Men

NCT01415375
View directory record Official record
Conditions
Prostate Cancer Screening Decision
Interventions
Prostate Cancer Screening Education, Fruit and Vegetable Intake Education
Behavioral
Lead sponsor
Temple University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 21, 2026, 7:02 AM EDT
Recruiting Phase 2 Interventional

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

NCT06439693
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
Interventions
Nab-Paclitaxel, Paclitaxel, Docetaxel, Phesgo, T-DM1, Pertuzumab, Trastuzumab Deruxtecan, Trastuzumab Subcutaneous Subcutaneous, Tucatinib, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Men and Women Offering Understanding of Throat HPV

NCT03644563
View directory record Official record
Conditions
Oropharyngeal Cancer, Human Papilloma Virus
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Active, not recruiting Phase 2 Interventional

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

NCT04777071
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography, Magnetic Resonance Imaging, Bone Scan, Electronic Health Record Review
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Enrolling by invitation Not applicable Interventional

Centralized Lung Cancer Screening Engagement in At-Risk Populations

NCT07216144
View directory record Official record
Conditions
Lung Cancer Screening
Interventions
Centralized patient outreach for lung cancer screening
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 21, 2026, 7:02 AM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06960395
View directory record Official record
Conditions
Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR
Interventions
VIR-5525, Pembrolizumab
Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Scottsdale, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

NCT00266877
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Interventions
HKI-272
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
11
States / cities
Los Angeles, California • Zion, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Screening CEDM in Intermediate and High-Risk Patient Populations

NCT03859492
View directory record Official record
Conditions
Breast Cancer
Interventions
Contrast Enhanced Digital Mammography
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older · Female only
Enrollment
461 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 21, 2026, 7:02 AM EDT
Active, not recruiting Not applicable Interventional

Impact of Patient-Centered Approach for Communicating Coronary Calcium on Cardiovascular Health

NCT06055972
View directory record Official record
Conditions
Coronary Artery Disease, Cardiovascular Diseases, Smoking
Interventions
Educational Letter Post CT Examination
Other
Lead sponsor
American College of Radiology
Other
Eligibility
50 Years to 80 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 21, 2026, 7:02 AM EDT
Active, not recruiting Not applicable Interventional

PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema

NCT05056207
View directory record Official record
Conditions
Lymphedema
Interventions
Cohort I (patients receiving annual lymphedema screening, Cohort II (patients followed intensively for lymphedema)
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

NCT05978128
View directory record Official record
Conditions
Breast Carcinoma, Lung Carcinoma
Interventions
Health Education, Health Promotion and Education, Patient Navigation, Survey Administration
Behavioral · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 21, 2026, 7:02 AM EDT
Active, not recruiting Phase 2 Interventional

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Osimertinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Active, not recruiting Phase 4 Interventional

C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics

NCT07220356
View directory record Official record
Conditions
Tobacco Dependence
Interventions
C-Raven Virtual Tobacco Cessation Counseling, Nicotine Replacement Product, Community Health Worker, Lung Cancer Screening
Behavioral · Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Not applicable Interventional

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

NCT01244568
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate cancer treatment DESI
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years and older · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 21, 2026, 7:02 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Community Gateway to Health Study

NCT07592793
View directory record Official record
Conditions
Breast Cancer Screening, Cervical Cancer Screening, Colon Cancer Screening, Tobacco Cessation
Interventions
Tools and Training for Cancer Control, Enhancing Social Capital and Civic Engagement
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Automated Breast Ultrasound

NCT02386176
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 21, 2026, 7:02 AM EDT
Recruiting Phase 1 Interventional

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

NCT06483048
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Carcinosarcoma, Recurrent Female Reproductive System Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinosarcoma, Refractory Fallopian Tube Carcinoma, Refractory Female Reproductive System Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions
Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Proactive Outreach and Shared Decision Making in Improving Lung Cancer Screening Rates in Primary Care Patients

NCT03929926
View directory record Official record
Conditions
Lung Cancer
Interventions
Best Practice, Cancer Educational Materials, Behavioral, Psychological or Informational Intervention, Counseling
Other · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
55 Years to 80 Years
Enrollment
2,355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 21, 2026, 7:02 AM EDT
Active, not recruiting Phase 2 Interventional

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

NCT04209660
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Salivary Gland Cancer
Interventions
Lenvatinib, Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Engagement With Messages Regarding CRC Screening Among Adults Aged 45-49

NCT05281159
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms
Interventions
Risk Information, Risk Information + Action
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 49 Years
Enrollment
20,509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 21, 2026, 7:02 AM EDT